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Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a
recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure
optimal access to specialty medications under Medicare Part D.
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KEY FINDINGS: Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not 
start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal 
access to specialty medications under Medicare Part D.
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THE FINDINGS
The first 30-day prescription fill of TKI had a mean price 
of $6,800; non-subsidized patients were required to pay 
approximately $2,600 out-of-pocket for the initial fill, while 
low-income subsidy (LIS) patients paid $5 or less. The high 
out-of-pocket costs of the first fill pushed non-subsidized 
patients out of the initial coverage phase and into the 
coverage gap phase. 
Non-subsidized beneficiaries were less likely than LIS 
beneficiaries to initiate TKI treatment within 6 months of 
their diagnosis with CML – 45% versus 67% respectively. 
Non-subsidized beneficiaries who did initiate TKI treatment 
took more than twice as long as LIS beneficiaries to do so – 
50.9 days versus 23.7 days respectively. 
The patient’s subsidy status remained highly associated 
with TKI initiation even when the authors controlled for 
sociodemographic, clinical and plan characteristics. These 
findings suggest that high cost sharing may impede access 
to life saving specialty drug treatment. It should be noted, 
however, that this was a cross-sectional analysis. The 
study documents associations and cannot establish a causal 
relationship between out-of-pockets costs and treatment 
initiation.
THE QUESTION
Does high cost sharing in Medicare Part D drug plans affect 
whether and how quickly patients initiate a recommended 
and life-extending drug treatment? LDI Senior Fellows 
Jalpa Doshi, Pengxiang Li and colleagues assess whether 
Medicare patients newly diagnosed with chronic myeloid 
leukemia (CML) and subject to significant coinsurance, take 
longer to initiate tyrosine kinase inhibitors (TKI) treatment 
than low-income (subsidized) Medicare patients subject to 
a nominal copayment. Oral TKIs allow most patients with 
CML to enjoy a near-normal life expectancy, and no lower-
cost option exists.
The complexity of the Medicare Part D benefits structure 
makes this research particularly relevant. In 2011-2015, non-
subsidized Medicare beneficiaries who needed a specialty 
drug faced coinsurance of 25%- 33% in the ‘initial coverage’ 
phase and 45%-50% in the ‘coverage gap’, also known 
as the ‘donut hole’. After patients reach a ‘catastrophic 
coverage limit’ ($4,550-$4,700 from 2011-2015), they pay 
5% coinsurance for the rest of that calendar year. 
 
THE STUDY
The authors used the 2011-2013 Medicare Chronic Condition 
Data Warehouse files, which contain data on all fee-for-service 
Medicare beneficiaries in the U.S. They identified 1,053 newly 
diagnosed CML patients using a series of claims-based selection 
criteria. The main outcome was the time to TKI initiation, or 
the number of days elapsed between the first date of CML 
diagnosis and the date that the first TKI prescription was filled. 
The authors compared initiation of TKI treatment among non-
subsidy Medicare beneficiaries against a comparison group of 
newly-diagnosed LIS patients. Extensive sensitivity analyses 
related to sample selection criteria, measuring time to TKI 
initiation, and analytic techniques confirmed the robustness of 
the findings.
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THE IMPLICATIONS
This study demonstrates how high out-of-pocket costs may 
limit or delay initiation of high-value treatments under 
Medicare Part D. It shows that the one-size-fits-all cost 
sharing in Medicare Part D plans, where cost sharing is 
directly a function of the medication cost, may serve as a 
barrier to patient initiation of specialty medications. 
This is the first study to utilize a full set of national Medicare 
Part A, B, and D fee-for-service claims linked with Part D 
plan and formulary information to explore the relationship 
between high cost sharing and access to specialty cancer 
drugs. Most prior evidence is out-of-date and focused on 
privately insured populations with lower levels of cost 
sharing.
The mean out-of-pocket payment for the first TKI 
prescription fill far exceeded the average monthly Social 
Security benefit (less than $1,350), which is the main source 
of income for many Medicare beneficiaries. Although the 
Affordable Care Act is meant to close the Part D coverage 
gap by 2020, patients will still be responsible for high rates of 
coinsurance, effectively extending the cost sharing currently 
in place for specialty drugs during the initial coverage phase. 
The authors suggest several policy fixes to protect patients 
against inordinately high out-of-pocket costs. These 
include: reducing beneficiary cost-sharing responsibility 
for drugs that have higher demonstrated efficacy and value; 
establishing an out-of-pocket spending maximum similar to 
many private insurance plans; and allowing beneficiaries to 
distribute total out-of-pocket costs more evenly throughout 
the year. 
THE STUDY
